A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal Follicular Lymphoma

NCT07736950 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

140

Enrollment

OTHER

Sponsor class

Conditions

Follicular Lymphoma

Interventions

DRUG: Surovatamig
RADIATION: Involved Site Radiotherapy (ISRT)
RADIATION: Involved-Site Radiotherapy (ISRT) + Rituximab

Sponsor

Australasian Leukaemia and Lymphoma Group